ConductScience.org, home

Paper10073742

Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.

Schäfers RF and 7 others. Br J Clin Pharmacol, 1999. Cited by 18 papers, by iCite.

Cite this record

ConductScience Library. Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin. Papers, record 10073742. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/10073742

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin.
PubMed
Journal
Br J Clin Pharmacol
PubMed
Year
1999
PubMed
Publication types
Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
0.77
iCite
Revised in PubMed
2019-05-13
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schäfers RFR F
2Fokuhl BB
3Wasmuth AA
4Schumacher HH
5Taguchi KK
6de Mey CC
7Philipp TT
8Michel MCM C

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adrenergic alpha-AntagonistsMajor topic
Blood PressureMajor topic
PrazosinMajor topic
SulfonamidesMajor topic
VasoconstrictionMajor topic
Adult
Cross-Over Studies
Drug Interactions
Hemodynamics
Humans
Male
Phenylephrine
Placebos
Single-Blind Method
Tamsulosin

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
15339656Development and evaluation of an impedance cardiac output system.Aerosp Med1966https://conductscience.org/library/papers/5339656PubMed
29720548Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?J Urol1998https://conductscience.org/library/papers/9720548PubMed
34042526Terazosin kinetics after oral and intravenous doses.Clin Pharmacol Ther1985https://conductscience.org/library/papers/4042526PubMed
42872802Pharmacokinetics of terazosin.Am J Med1986https://conductscience.org/library/papers/2872802PubMed
51981137An evaluation of the alpha-adrenoceptor antagonism produced by SK&F 86466 in healthy normotensive males.Br J Clin Pharmacol1990https://conductscience.org/library/papers/1981137PubMed
61683249Studies with abanoquil (UK-52,046) a novel quinoline alpha 1-adrenoceptor antagonist: I. Effects on blood pressure, heart rate and pressor responsiveness in normotensive subjects.Br J Clin Pharmacol1991https://conductscience.org/library/papers/1683249PubMed
71279214A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.J Urol1992https://conductscience.org/library/papers/1279214PubMed
87509243Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group.Arch Fam Med1993https://conductscience.org/library/papers/7509243PubMed
97858860Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery.Br J Pharmacol1994https://conductscience.org/library/papers/7858860PubMed
107881752Characterization of alpha 1-adrenoceptors mediating vasoconstriction to noradrenaline and nerve stimulation in the isolated perfused mesentery of rat.Br J Pharmacol1995https://conductscience.org/library/papers/7881752PubMed
117537194Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.Drugs1995https://conductscience.org/library/papers/7537194PubMed
127542819Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.Urology1995https://conductscience.org/library/papers/7542819PubMed
137543612alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia.J Urol1995https://conductscience.org/library/papers/7543612PubMed
147670730Functional evidence equating the pharmacologically-defined alpha 1A- and cloned alpha 1C-adrenoceptor: studies in the isolated perfused kidney of rat.Br J Pharmacol1995https://conductscience.org/library/papers/7670730PubMed
157477417Classification of alpha 1-adrenoceptor subtypes.Naunyn Schmiedebergs Arch Pharmacol1995https://conductscience.org/library/papers/7477417PubMed
167491088Vascular alpha-1 adrenergic receptor subtypes in the regulation of arterial pressure.Life Sci1995https://conductscience.org/library/papers/7491088PubMed
178607227The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.Urology1996https://conductscience.org/library/papers/8607227PubMed
188647139Selective alpha 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience.Eur Urol1996https://conductscience.org/library/papers/8647139PubMed
198647141
Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.
Eur Urol1996https://conductscience.org/library/papers/8647141PubMed
208692287Effects of noradrenaline and neuropeptide Y on rat mesenteric microvessel contraction.Naunyn Schmiedebergs Arch Pharmacol1996https://conductscience.org/library/papers/8692287PubMed

See all 34 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
21745239Tamsulosin shows a higher unbound drug fraction in human prostate than in plasma: a basis for uroselectivity?Br J Clin Pharmacol2011https://conductscience.org/library/papers/21745239PubMed
11950378Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.Drugs Aging2002https://conductscience.org/library/papers/11950378PubMed
11790159Tamsulosin: an update of its role in the management of lower urinary tract symptoms.Drugs2002https://conductscience.org/library/papers/11790159PubMed
11422021A 6-month large-scale study into the safety of tamsulosin.Br J Clin Pharmacol2001https://conductscience.org/library/papers/11422021PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/10073742

GET https://conductscience.org/api/papers/v1/10073742/references?page=2